<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949624</url>
  </required_header>
  <id_info>
    <org_study_id>A5301005</org_study_id>
    <nct_id>NCT00949624</nct_id>
  </id_info>
  <brief_title>CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and
      tolerability of adding targeted agents to a standard chemotherapy. CP-868,596 is a
      platelet-derived growth factor receptor inhibitor (PDGFR) and AG-13736 is a vascular
      endothelial growth factor receptor inhibitor (VEGFR). This study will test the use of
      docetaxel (the standard chemotherapy) with either CP-868,596 or the combination of CP-868,596
      and AG-13736.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First-cycle Dose Limiting Toxicities</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety and tolerability of the combination of daily CP‑868,596 and docetaxel on an every 3‑week schedule</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety and tolerability of the combination of daily CP‑868,596 plus daily AG‑013736 plus docetaxel on an every 3‑week schedule</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) of CP‑868,596 and docetaxel when given in combination</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) of CP‑868,596, AG‑013736 and docetaxel when given in combination</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduct biomarker investigations on plasma/serum samples to explore critical events in pharmacodynamic response to CP‑868,596 (eg, VEGF, phospho‑SHP, etc.)</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the relationship between polymorphisms in genes involved in the metabolism and transport of CP‑868,596 and pharmacokinetic/pharmacodynamic parameters</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effects of CP‑868,596 on tumor blood flow and permeability via DCE‑MRI</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess any preliminary clinical evidence of anti‑tumor activity using RECIST</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg BID/ 75 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg BID/75 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg BID/100 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-868,596 + AG-013736 + TXT 75</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-868,596</intervention_name>
    <description>Oral tablet 60 mg BID continuous</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous 75 mg/m2 every three weeks</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-868,596</intervention_name>
    <description>Oral tablet 100 mg BID continuous</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous 75 mg/m2 every three weeks</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-868,596</intervention_name>
    <description>Oral tablet 100 mg BID continuous</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous 100 mg/m2 every three weeks</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-868,596</intervention_name>
    <description>Oral tablet 60 mg BID continuous</description>
    <arm_group_label>Cohort 4b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-013736</intervention_name>
    <description>Oral tablet 5 mg BID continuous</description>
    <arm_group_label>Cohort 4b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous 75 mg/m2 every three weeks</description>
    <arm_group_label>Cohort 4b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be ≥18 years old and with histologically or cytologically confirmed advanced solid
             tumors refractory/resistant to currently available therapies or for which there is no
             standard therapy.

          -  Patients with primary brain tumors are not eligible.

          -  Have at least one site of measurable disease.

        Exclusion Criteria:

          -  Received chemotherapy (including targeted agents such as erlotinib), radiotherapy,
             immunotherapy or any investigational therapy within 3 weeks of study entry (within 6
             weeks for previous treatments with nitrosoureas or mitomycin C).

          -  Received tamoxifen within 4 weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5301005&amp;StudyName=CP-868%2C596%20And%20CP-868%2C596%20Plus%20AG-013736%20In%0ACombination%20With%20Docetaxel%20In%20Advanced%20Solid%20Tumors%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDGFr Inhibition;</keyword>
  <keyword>VEGFr inhibition;</keyword>
  <keyword>targeted therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Crenolanib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

